Skip to main content
Print Save

Generic Victoza Availability

Last updated on Jan 11, 2023.

Victoza is a brand name of liraglutide, approved by the FDA in the following formulation(s):

VICTOZA (liraglutide recombinant - solution;subcutaneous)

  • Manufacturer: NOVO NORDISK INC
    Approval date: January 25, 2010
    Strength(s): 18MG/3ML (6MG/ML) [RLD]

Has a generic version of Victoza been approved?

No. There is currently no therapeutically equivalent version of Victoza available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Victoza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Derivatives of GLP-1 analogs
    Patent 6,268,343
    Issued: July 31, 2001
    Inventor(s): Knudsen; Liselotte Bjerre & Huusfeldt; Per Olaf & Nielsen; Per Franklin & Kaarsholm; Niels C. & Olsen; Helle Birk & Bj.o slashed.rn; S.o slashed.ren Erik & Pedersen; Freddy Zimmerdahl & Madsen; Kjeld
    Assignee(s): Novo Nordisk A/S

    The present invention relates to GLP-1 derivatives having a lipophilic substituent, pharmaceutical compositions comprising same, and methods of making an using same. The GLP-1 derivatives of the present invention have a protracted profile of action.

    Patent expiration dates:

    • August 22, 2022
      ✓ 
      Patent use: A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • February 22, 2023
      ✓ 
      Pediatric exclusivity
  • Needle mounting system and a method for mounting a needle assembly
    Patent 7,762,994
    Issued: July 27, 2010
    Inventor(s): Klint; Henrik Sonderskov & Radmer; Jim & Smedegaard; Jorgen K & Nielsen; Jan Frank & Jensen; Peter Moller & Jensen; Jens Moller
    Assignee(s): Novo Nordisk A/S

    A needle mounting system and methods for mounting a needle assembly on a needle mount are disclosed. The needle mounting system includes a needle hub having protrusions extending radially inward. A needle mount has a plurality of slots to receive the protrusions. The slots have a first portion that defines a passageway substantially parallel to a longitudinal axis of the needle mount and a second portion substantially perpendicular to the axis. The needle hub and mount provide a method wherein a needle assembly may be mounted on an injection device without completely rotating the needle hub relative to the needle mount.

    Patent expiration dates:

    • May 23, 2024
      ✓ 
      Drug product
    • November 23, 2024
      ✓ 
      Pediatric exclusivity
  • Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
    Patent 8,114,833
    Issued: February 14, 2012
    Inventor(s): Pedersen; Tina Bjeldskov & Bonde; Claude & Engelund; Dorthe Kot
    Assignee(s): Novo Nordisk A/S

    The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation.

    Patent expiration dates:

    • August 13, 2025
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • February 13, 2026
      ✓ 
      Pediatric exclusivity
  • Needle mounting system and a method for mounting a needle assembly
    Patent 8,579,869
    Issued: November 12, 2013
    Assignee(s): Novo Nordisk A/S

    A needle mounting system and methods for mounting a needle assembly on a needle mount are disclosed. The needle mounting system includes a needle hub having protrusions extending radially inward. A needle mount has a plurality of slots to receive the protrusions. The slots have a first portion that defines a passageway substantially parallel to a longitudinal axis of the needle mount and a second portion substantially perpendicular to the axis. The needle hub and mount provide a method wherein a needle assembly may be mounted on an injection device without completely rotating the needle hub relative to the needle mount.

    Patent expiration dates:

    • June 30, 2023
      ✓ 
      Drug product
    • December 30, 2023
      ✓ 
      Pediatric exclusivity
  • Stable formulation of modified GLP-1
    Patent 8,846,618
    Issued: September 30, 2014
    Assignee(s): Novo Nordisk A/S

    Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof.

    Patent expiration dates:

    • June 27, 2022
      ✓ 
      Drug product
    • December 27, 2022
      ✓ 
      Pediatric exclusivity
  • Injection button
    Patent 9,265,893
    Issued: February 23, 2016
    Assignee(s): Novo Nordisk A/S

    A push button connection for an injection device comprising a push button (10) and a driving part (20). The two parts of the push button connection are mounted to each other and is relatively rotatable to each other. In order to minimize the friction occurring between the push button and the driving part when relatively rotated forces are transmitted via a pivot bearing (18, 22). In order also to minimize the effect of forces appearing dislocated from the center line a number of radial bearings (13, 23; 14, 25) having a little friction diameter is provided.

    Patent expiration dates:

    • September 23, 2032
      ✓ 
      Drug product
    • March 23, 2033
      ✓ 
      Pediatric exclusivity
  • Liraglutide in cardiovascular conditions
    Patent 9,968,659
    Issued: May 15, 2018
    Assignee(s): Novo Nordisk A/S

    The present invention relates to the GLP-1 receptor agonist liraglutide for use in medicine.

    Patent expiration dates:

    • January 9, 2037
      ✓ 
      Patent use: METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE
    • July 9, 2037
      ✓ 
      Pediatric exclusivity

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • June 17, 2022 - NEW PATIENT POPULATION
    • December 17, 2022 - PEDIATRIC EXCLUSIVITY

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer